Recent market developments indicate that Jiangsu AB&B BIO-TECH Biotechnology Co., Ltd., known as AB&B BIO-TECH-B (02627), has achieved further success with its independently developed trivalent influenza virus subunit vaccine—the first and only such vaccine in China designed for all age groups and dosages. Following successful bids for non-immunization program vaccine procurement projects in Shanxi and Gansu provinces, the vaccine, branded as Huier Kangxin 3, has now been selected for the 2026 supplementary procurement programs in Yunnan and Fujian provinces at a price of 298 yuan per dose. These consecutive successful bids not only reflect the agility of AB&B BIO-TECH-B’s commercial team amid market fluctuations but also demonstrate the company’s steady performance execution capability. As product access continues to expand, AB&B BIO-TECH-B will provide safer and higher-quality vaccine protection to a broader population during the 2026–2027 flu season.
With the World Health Organization (WHO) officially releasing the recommended composition for the Northern Hemisphere’s 2026–2027 seasonal influenza vaccine, the market is expected to transition toward a trivalent era. Leveraging sharp industry insight and strong R&D conversion capabilities, AB&B BIO-TECH-B has strategically positioned itself to introduce the country’s first and only pan-population, full-dose trivalent influenza subunit vaccine. This product, together with the company’s already marketed quadrivalent influenza subunit vaccine, forms a dual high-end influenza vaccine line, seamlessly aligning with policy trends and offering a more precise and safer protection alternative.
As a third-generation influenza vaccine, Huier Kangxin 3 extracts only the virus's surface core antigens (HA/NA), eliminating internal viral impurities. This results in higher purity, fewer adverse reactions, improved safety, and superior immune response. Phase III clinical data indicate that local adverse reactions are lower compared to traditional split-virus vaccines. Full-dose administration provides stronger immune protection for infants and young children, with a favorable safety profile. Additionally, Huier Kangxin 3 breaks new ground by enabling a uniform 0.5ml dosage for individuals aged six months and above, simplifying vaccination procedures for both infants and adults and enhancing operational efficiency for healthcare workers.
AB&B BIO-TECH-B is currently accelerating market access for its trivalent influenza subunit vaccine, actively expanding coverage to ensure continuous supply of high-quality influenza vaccines to more provinces and municipalities. This effort aims to strengthen public immunity and offer professional, reliable health protection to more families.
Comments